Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (Nadroparin)

Thrombosis and Haemostasis

Volumn 79, Issue 6, 1998, Pages 1162-1165

  Mismetti, P ^a   Laporte Simitsidis, S ^a   Navarro, C ^b   Sie P ^b   D'Azemar, P ^c   Necciari, J ^c   Duret, J P ^c   Gaud, C ^c   Decousus, H ^a   Boneu, B ^d,e  

^a University Jean Monnet of Saint Etienne EA3065   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

^c SANOFI   (France)

^d Lab Rech sur l'Hemostase T   (France)

^e CHU PURPAN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A; CREATININE; NADROPARIN;

ADULT; AGED; AGING; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DEEP VEIN THROMBOSIS; DRUG PROTEIN BINDING; FEMALE; HUMAN; MALE; PHARMACODYNAMICS; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOEMBOLISM;

EID: 0031832877     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1615034     Document Type: Article

References (16)

1. Leizorovicz A, Simonneau G, Decousus H, Boissel JP. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta-analysis. Br Med J 1994; 309: 299-304.
2. Lensing AWA, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparins. Arch Intern Med 1995; 155: 601-7.
3. Boneu B. Low molecular weight heparin therapy: Is monitoring needed? Thromb Haemost 1994; 72: 330-4.
4. Hull RD, Raskob GE, Pineo GF, Green D, Trowbridge AA, Elliott CG, Lerner RG, Hall J, Sparling T, Bretell HR, Norton J, Carter CJ, George R, Merli G, Ward J, Mayo W, Rosenblomm D, Brant R. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992; 326: 975-82.
5. Holmström M, Berglund MC, Granquist S, Bratt G, Törnebohm E, Lockner D. Fragmin, once or twice daily subcutaneously in the treatment of deep vein thrombosis of the leg. Thromb Res 1992; 67: 49-55.
6. Lindmarker P, Holmström M, Granqvist S, Johnsson H, Lockner D. Comparison of once-daily subcutaneous Fragmin® with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost 1994; 72: 186-90.
7. Fiessinger JN, Lopez-Fernandez M, Gatterer E, Granqvist S, Kher A, Olsson CG, Söderberg K. Once-daily subcutaneous Dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis. Thromb Haemost 1996; 76: 195-9.
8. Charbonnier BA, Fiessinger JN, Sixma JJ, d'Azemar P, Sagnard L. Comparison of a once daily versus twice daily subcutaneous Nadroparin calcium regimens in the treatment of deep vein thrombosis. On behalf of the Fraxodi group. Circulation 1996; 94: 742 (abst).
9. Pioped investigators. Value of the ventilation/perfusion scan in acute pulmonary embolism: results of the prospective investigation of pulmonary embolism diagnosis (Piomed). JAMA 1990; 263: 2753-9.
10. Briant L, Caranobe C, Saivin S, Sié P, Bayrou B, Houin G, Boneu B. Unfractionated heparin and CY216: pharmacokinetics and bioavailabilities of the antifactor Xa and antithrombin effects after intravenous and subcutaneous injection in the rabbit. Thromb Haemost 1989; 61: 348-53.
11. Boneu B, Necciari J, Cariou R, Sié P, Gabaig AM, Kieffer G, Dickinson J, Lamond G, Moelker H, Mant T, Magnani H. Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/ORG31540) with high affinity to antithrombin III in man. Thromb Haemost 1995; 74: 1468-73.
12. Boneu B, Caranobe C, Saivin S, Dol F, Sié P. Pharmacokinetics of heparin and of dermatan sulfate: clinical implications. In: Heparins and Related Polysaccharides. Lane DA, Björk I, Lindhal U (eds). Plenum Press, New York 1992; pp 237-47.
13. Peyrou P, Lormeau JC, Caranobe C, Gabaig AM, Crepon B, Saivin S, Houin G, Sie P, Boneu B. Pharmacological properties of CY 216 and of its ACLM and BCLM components in the rabbit. Thromb Haemost 1994; 72: 268-74.
14. Young E, Cosmi B, Weitz J, Hirsh J. Comparison of the non specific binding of unfractionated heparin and low molecular weight heparin (Enoxaparin) to plasma proteins. Thromb Haemost 1993; 70: 625-30.
15. Cosmi B, Fredenburgh J, Rischke J, Hirsh J, Young E, Weitz J. Effect of nonspecific binding to plasma proteins on the antithrombin activities of unfractionated heparin, low-molecular-weight heparin, and dermatan sulfate. Circulation 1997; 95: 118-24.
16. Young E, Prins M, Levine MN, Hirsh J. Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb Haemost 1992; 67: 639-43.